MSUD crisis is a life-threatening metabolic emergency caused by accumulation of neurotoxic branched-chain amino acids (BCAAs: leucine, isoleucine, valine) and their alpha-ketoacids due to deficiency of the branched-chain alpha-ketoacid dehydrogenase (BCKD) complex. Leucine is the primary neurotoxic metabolite. Acute decompensation can progress to cerebral edema, coma, and death within days if untreated. [1]
1. History
- Known MSUD patient? Confirm subtype (classic, intermediate, intermittent, thiamine-responsive) and baseline leucine tolerance [1]
- Precipitating catabolic stress: Infection (most common), surgery, trauma, fasting, dietary indiscretion, psychological stress, or vaccination [1]
- Symptom timeline: Onset of poor feeding, anorexia, vomiting, lethargy, irritability — often 24–48 hours into illness [2-3]
- Dietary compliance: Recent protein intake, adherence to BCAA-restricted diet, use of sick-day formula [1]
- Maple syrup odor: Sweet smell in urine, cerumen, or on body — pathognomonic [1]
- Neonatal presentation (if undiagnosed): Progressive encephalopathy over days 2–10 of life [1]
2. Alarm Features
- Altered consciousness — lethargy progressing to obtundation or coma [1]
- Apnea or irregular respirations — suggests brainstem involvement or impending central respiratory failure [1]
- Opisthotonus, "fencing" or "bicycling" movements — stereotyped posturing from severe leucinosis [1]
- Acute focal or generalized dystonia — attributed to elevated leucine:tyrosine ratio and reduced cerebral dopamine synthesis [1]
- Signs of cerebral edema — headache, vomiting, papilledema, Cushing triad, decreasing GCS [1][4]
- Rapidly declining serum sodium/osmolality — strongly associated with progression of cerebral edema [5]
- Seizures [6]
3. Medications
- During crisis:
- IV dextrose (D10–D25) ± insulin to promote anabolism and suppress protein catabolism [1]
- Isoleucine and valine supplements (20–120 mg/kg/day each, enteral + parenteral) — prevents deficiency and sustains protein synthesis; titrate to plasma levels 400–800 µmol/L [1]
- BCAA-free amino acid solutions (enteral or IV, 0.5–2.6 g/kg/day) [2][7]
- Mannitol (0.5–1 g/kg/dose), hypertonic (3%) saline (2–3 mEq/kg/dose), furosemide (0.5–1 mg/kg/dose) for cerebral edema [1][5]
- Sodium phenylbutyrate — emerging adjunct; leucine reduction rates of ~530 µmol/L/day at 24 hours reported [8]
- Empiric antibiotics — low threshold when infection suspected; Candida infections are common with central lines [1]
- Contraindicated/caution:
- Avoid hypotonic IV fluids (risk of hyponatremia → cerebral edema) [1][5]
- Avoid high-protein feeds or TPN containing BCAAs
- Never protein-challenge a suspected MSUD patient [1]
4. Diet
- Acute crisis: Complete cessation of dietary leucine; switch to BCAA-free "sick-day" formula enriched with calories, isoleucine, valine, and BCAA-free amino acids [1]
- High caloric intake is essential — provide ≥100–120% of estimated energy expenditure via dextrose, lipids, and BCAA-free formula to suppress catabolism [1][5]
- Reintroduction: Stepwise reintroduction of dietary leucine once plasma leucine falls to therapeutic range (100–300 µmol/L) [5]
- Long-term: Lifelong BCAA-restricted diet with medical formula supplementation; leucine tolerance varies by subtype and age [1]
5. Review of Systems
- Neurologic: Level of consciousness, irritability, seizures, abnormal movements, ataxia, hallucinations, mood changes [1]
- GI: Nausea, vomiting, anorexia, poor feeding, epigastric/mid-back pain (pancreatitis can develop 2–3 days into treatment) [1]
- Respiratory: Apnea, irregular breathing pattern [1]
- Constitutional: Fever, malaise, dehydration [3]
- Psychiatric (older patients): Cognitive impairment, hyperactivity, sleep disturbances, mood swings [1]
6. Collateral History and Family History
- Autosomal recessive inheritance — consanguinity increases risk; inquire about affected siblings [9-10]
- Newborn screening results — confirm whether NBS was performed and result [1]
- Prior episodes of decompensation — frequency, triggers, severity, need for dialysis [11]
- Metabolic specialist and dietitian contacts — essential for coordinating care [1]
- Genotype if known (BCKDHA, BCKDHB, or DBT mutations) [1]
7. Risk Factors
- Classic MSUD (0–2% residual BCKD activity) — highest risk for severe crisis [1]
- Intercurrent infection — most common precipitant at any age [1]
- Fasting or inadequate caloric intake [2]
- Surgery, trauma, or physiologic stress [1]
- Dietary noncompliance — especially during adolescence [12]
- Certain populations: Higher incidence in Old Order Mennonite communities (~1:380 live births) [5]
- Incidence: ~1:100,000–300,000 in general population [13]
8. Differential Diagnosis
- Other organic acidemias (propionic acidemia, methylmalonic acidemia) — similar ketoacidosis and encephalopathy but different metabolite profiles [14]
- Urea cycle defects — hyperammonemia predominates; BCAAs not elevated [15]
- Diabetic ketoacidosis — ketonuria and acidosis overlap; check glucose and BCAAs
- Sepsis/meningitis — especially in neonates with lethargy and poor feeding
- Non-accidental trauma — in encephalopathic infants
- Other causes of neonatal encephalopathy — hypoxic-ischemic encephalopathy, inborn errors of energy metabolism
- Hydroxyprolinemia — can cause false-positive NBS for MSUD (leucine-isoleucine and hydroxyproline are indistinguishable by MS/MS) [1]
9. Past Medical History
- Prior metabolic crises — number, severity, ICU admissions, need for dialysis [11]
- Baseline neurologic status — developmental milestones, IQ, psychiatric comorbidities (ADHD, depression, anxiety are common) [1][11]
- Liver transplant status — transplanted patients have ~10% restored BCKD activity and are protected from severe crises but not immune to mild elevations [10-11]
- Central line history — prior PICC/central line infections [1]
- Pancreatitis history — known complication during treatment of decompensation [1]
10. Physical Exam
- Vital signs: Fever (infection trigger), tachycardia, irregular respirations, apnea
- General: Maple syrup odor on body/urine/cerumen — pathognomonic [1]
- Neurologic:
- Level of consciousness (GCS)
- Tone — hypotonia or hypertonia/opisthotonus
- Stereotyped movements: "fencing," "bicycling" [1]
- Focal or generalized dystonia [1]
- Ataxia, choreoathetosis (older children/adults) [1]
- Pupillary response, fundoscopy for papilledema
- Fontanelle (infants): Bulging suggests raised ICP
- Hydration status: Mucous membranes, skin turgor, capillary refill
- Abdominal exam: Epigastric tenderness (pancreatitis) [1]
11. Lab Studies
- Stat plasma amino acids — leucine is the critical value; crisis typically presents with leucine ≥381 µmol/L (often >750–2000+ µmol/L); alloisoleucine is pathognomonic for MSUD [1][7-8]
- Urine organic acids — elevated branched-chain alpha-ketoacids (BCKAs) [1]
- Urine ketones (dipstick or DNPH test) — ketonuria is an early marker [1-2]
- Basic metabolic panel: Anion gap metabolic acidosis; monitor sodium closely (target 138–145 mEq/L) [1][5]
- Serum osmolality — maintain 275–300 mOsm/kg; prevent drops >5 mOsm/kg/day [1]
- Glucose — every 4–6 hours (hyperglycemia from dextrose/insulin; hypoglycemia also possible) [1]
- Uric acid — elevated; correlates with leucine levels and is a useful ED biomarker for decompensation [3]
- Serum phosphorus, magnesium — every 12–24 hours (iatrogenic depletion common) [1]
- Lipase, amylase, transaminases — every 24–48 hours (pancreatitis surveillance) [1]
- Blood gas — metabolic acidosis with elevated anion gap [3]
- Infection workup — CBC, blood culture, urinalysis, CRP/procalcitonin as indicated [1]
12. Imaging
- Cranial CT (first-line in acute crisis) — evaluate for cerebral edema: decreased ventricular volume, loss of gray-white differentiation, effacement of basal cisterns [1]
- Brain MRI (when stable) — cytotoxic edema with restricted diffusion on DWI; symmetric involvement of brainstem, cerebellar white matter, basal ganglia, thalamus, and cerebral peduncles [16]
- Imaging is not always necessary — clinical and biochemical monitoring guides management; imaging is indicated when there is concern for cerebral edema or herniation [1]
13. Special Tests
- DNPH (dinitrophenylhydrazine) urine test — rapid bedside screen for BCKAs; positive in crisis [1]
- Urine ketone dipstick — early indicator of catabolism [2]
- Tandem mass spectrometry (MS/MS) — newborn screening and confirmatory testing; measures leucine + isoleucine/alanine and phenylalanine ratios [1][17]
- Genetic testing — biallelic pathogenic variants in BCKDHA, BCKDHB, or DBT confirm diagnosis [1]
- Thiamine responsiveness trial — enteral thiamine supplementation to identify thiamine-responsive subtype [1]
14. ECG
- Not a primary diagnostic tool in MSUD crisis
- Obtain ECG if:
- Electrolyte derangements (hypokalemia, hypophosphatemia, hypomagnesemia) — risk of arrhythmia [1]
- Hemodynamic instability
- Monitor for QT prolongation in setting of electrolyte shifts during aggressive IV therapy
15. Assessment
MSUD crisis is a metabolic emergency driven by uncontrolled protein catabolism leading to toxic leucine accumulation. Severity correlates with:
- Plasma leucine level and rate of rise [1]
- Rate of decline in serum osmolality — more directly related to cerebral edema risk than absolute leucine level [1][5]
- Degree of encephalopathy — ranges from irritability/malaise to coma and central respiratory failure [1]
Key complications to anticipate:
- Cerebral edema → herniation and death (leading cause of mortality) [1][4]
- Iatrogenic complications of treatment: hyperglycemia, hypoglycemia, hyponatremia, hypokalemia, hypophosphatemia [1]
- Pancreatitis — typically develops 2–3 days into treatment [1]
- Central line infections (bacterial and Candida) [1]
16. Treatment Plan
Initial stabilization
- ABCs — intubate if obtunded with impaired airway protection [1]
- Establish central venous access (PICC or central line preferred) [1]
- Identify and treat precipitating catabolic stress (empiric antibiotics if infection suspected) [1]
Metabolic management — promote anabolism and reduce leucine:
- High-calorie IV dextrose (D10–D25) ± insulin infusion to drive anabolism [1]
- BCAA-free amino acid solution — enteral (via NG if needed) or IV (0.5–2.0 g/kg/day); IV formulations available from specialty pharmacies [1][7]
- Isoleucine and valine supplements (20–120 mg/kg/day each) — critical to prevent deficiency and sustain protein synthesis; titrate to plasma levels 400–800 µmol/L [1]
- Target leucine reduction: 500–1,000 µmol/L per 24 hours [1]
Cerebral edema management
- Isotonic fluids only — establish euvolemia with normal saline [1]
- Serum osmolality monitoring every 6–12 hours; prevent decline >5 mOsm/kg/day [1]
- Mannitol 0.5–1 g/kg, 3% saline 2–3 mEq/kg, furosemide 0.5–1 mg/kg — alone or in sequence for rising ICP [1]
- Neurosurgical consultation for ICP monitoring/CSF drainage in obtunded patients [1]
Renal replacement therapy (if available)
- Continuous hemodialysis is most effective extracorporeal method — can achieve >90% leucine reduction in 2 sessions [15][18]
- Must be coupled with simultaneous nutritional management — dialysis alone without anabolic support is insufficient (analogous to treating DKA without insulin) [1]
- Consider when: leucine >2,500 µmol/L, comatose patient not responding to nutritional therapy, or clinical deterioration [2][18]
17. Disposition
- Admit to ICU for:
- Any altered mental status or encephalopathy [1]
- Plasma leucine >1,000 µmol/L with neurologic symptoms
- Inability to tolerate enteral feeds (vomiting, coma) [7]
- Need for hemodialysis or ICP monitoring [1][15]
- Cerebral edema on imaging [4]
- Admit to monitored bed for:
- Moderate leucine elevation (381–1,000 µmol/L) with preserved mentation
- Requirement for IV BCAA-free solution or glucose/insulin infusion
- Outpatient management may be attempted for ≤12 hours only if: [1]
- Fever <38.5°C
- Tolerating enteral feeds without recurrent vomiting
- No neurologic symptoms
- Able to take BCAA-free sick-day formula
- Close monitoring with DNPH urine strips and amino acid levels every 24–48 hours
- Metabolic specialist consultation is mandatory for all decompensation episodes [1]
18. Follow Up / Return Precautions
- Plasma amino acids every 12–24 hours during hospitalization; continue until leucine <381 µmol/L and trending down [1]
- Post-discharge: Stepwise reintroduction of dietary leucine over 48–72 hours once leucine is in therapeutic range (100–300 µmol/L) [1][5]
- Amino acid monitoring: Weekly (or twice weekly in infants) after discharge [1]
- Follow-up with metabolic specialist within days of discharge [1]
- Return immediately for: Recurrent vomiting, inability to take formula, lethargy, altered behavior, maple syrup odor, fever >38.5°C, or any neurologic symptoms [1]
- Long-term surveillance: Developmental milestones, neurocognitive testing, calcium/magnesium/zinc/folate/selenium/omega-3 levels, and psychiatric screening (ADHD, depression, anxiety) [1]
- Liver transplantation should be discussed for patients with recurrent severe crises — provides ~10% BCKD restoration, eliminates need for restricted diet, and prevents future crises, but does not reverse pre-existing neurological damage [10-11]
Images
References
1. Maple Syrup Urine Disease. — Strauss KA, Puffenberger EG, Carson VJ GeneReviews® [Internet]. 2020.
2. Branched-Chain Amino Acid-Free Parenteral Nutrition in the Treatment of Acute Metabolic Decompensation in Patients with Maple Syrup Urine Disease. — Berry GT, Heidenreich R, Kaplan P, et al. The New England Journal of Medicine. 1991.
3. Predictors of Acute Metabolic Decompensation in Children With Maple Syrup Urine Disease at the Emergency Department. — Yıldız Y, Akcan Yıldız L, Dursun A, et al. European Journal of Pediatrics. 2020.
4. Cerebral Edema in Maple Syrup Urine Disease: Spectrum of Clinical Presentation and Treatment Outcomes. — Sulaiman RA, Altassan R, Alshammari R, et al. Orphanet Journal of Rare Diseases. 2025.
5. Diagnosis and Treatment of Maple Syrup Disease: A Study of 36 Patients. — Morton DH, Strauss KA, Robinson DL, Puffenberger EG, Kelley RI. Pediatrics. 2002.
6. Pathophysiology of Maple Syrup Urine Disease: Focus on the Neurotoxic Role of the Accumulated Branched-Chain Amino Acids and Branched-Chain Α-Keto Acids. — Amaral AU, Wajner M. Neurochemistry International. 2022.
7. Intravenous Administration of a Branched-Chain Amino-Acid-Free Solution in Children and Adults With Acute Decompensation of Maple Syrup Urine Disease: A Prospective Multicentre Observational Study. — Alili JM, Berleur MP, Husson MC, et al. Orphanet Journal of Rare Diseases. 2022.
8. Impact of Sodium Phenylbutyrate Treatment in Acute Management of Maple Syrup Urine Disease Attacks: A Single-Center Experience. — Zubarioglu T, Dede E, Cigdem H, et al. Journal of Pediatric Endocrinology & Metabolism : JPEM. 2021.
9. Maple syrup urine disease. — National Library of Medicine (MedlinePlus) 2017.
10. Treatment of Maple Syrup Urine Disease: Benefits, Risks, and Challenges of Liver Transplantation. — Deon M, Guerreiro G, Girardi J, Ribas G, Vargas CR. International Journal of Developmental Neuroscience : The Official Journal of the International Society for Developmental Neuroscience. 2023.
11. Branched-Chain Α-Ketoacid Dehydrogenase Deficiency (Maple Syrup Urine Disease): Treatment, Biomarkers, and Outcomes. — Strauss KA, Carson VJ, Soltys K, et al. Molecular Genetics and Metabolism. 2020.
12. Maple Syrup Urine Disease: Clinical Outcomes, Metabolic Control, and Genotypes in a Screened Population After Four Decades of Newborn Bloodspot Screening in the Republic of Ireland. — O'Reilly D, Crushell E, Hughes J, et al. Journal of Inherited Metabolic Disease. 2021.
13. Quantification of Branched-Chain Amino Acids in Plasma by High-Performance Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS). — Piri-Moghadam H, Miller A, Pronger D, et al. Methods in Molecular Biology. 2022.
14. Inherited Metabolic Disorders and Stroke Part 2: Homocystinuria, Organic Acidurias, and Urea Cycle Disorders. — Testai FD, Gorelick PB. Archives of Neurology. 2010.
15. Acute Hemodialysis Therapy in Neonates With Inborn Errors of Metabolism. — Eisenstein I, Pollack S, Hadash A, et al. Pediatric Nephrology. 2022.
16. Neonatal Maple Syrup Urine Disease Case Report and Literature Review. — Liu Q, Li F, Zhou J, et al. Medicine. 2022.
17. Newborn Screening of Maple Syrup Urine Disease and the Effect of Early Diagnosis. — Chen T, Lu D, Xu F, et al. Clinica Chimica Acta; International Journal of Clinical Chemistry. 2023.
18. Combined Nutritional Support and Continuous Extracorporeal Removal Therapy in the Severe Acute Phase of Maple Syrup Urine Disease. — Jouvet P, Jugie M, Rabier D, et al. Intensive Care Medicine. 2001.